About us
Founded in 2012 and granted the qualification of biomedicine company by the Ministry of Economic Affairs in 2015, Energenesis Biomedical Co., Ltd. aspires to become a new star in biotech industry.
Information
- 2025-12 Energenesis Biomedical Wins the 22nd Taiwan National Innovation Award
- 2025-11 Energenesis Biomedical Receives FDA Clearance for Phase II Trial of ENERGI-F703EB
- 2025-10 Energenesis Biomedical Announces IND Submission to the U.S. FDA for Phase II Clinical Trial of ENERGI-F703EB Cream
- 2025-10 Energenesis Biomedical is invited to attend Taishin’s “2025 Investor Conference"
- 2025-07 Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease